Avadel Pharmaceuticals plc (AVDL)
21.64
+0.01 (0.05%)
Inactive · Last trade price on Feb 11, 2026
Avadel Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -0.28 | -48.83 | -160.28 | -137.46 | -77.33 | 7.03 |
Depreciation & Amortization | 3.68 | 2.68 | 1.77 | 1.49 | 0.82 | 1.69 |
Stock-Based Compensation | 18.56 | 20.39 | 15.81 | 7.01 | 8.87 | 3 |
Other Adjustments | -0.82 | -0.83 | 17.19 | 34.12 | -13.36 | -46.13 |
Change in Receivables | -5.34 | -21.99 | -12.1 | - | - | 8.28 |
Changes in Inventories | -8.01 | -9.22 | -9.53 | - | - | -1.35 |
Changes in Accounts Payable | 4.49 | -4.09 | 1.55 | -3.11 | 4.23 | -2.79 |
Changes in Accrued Expenses | 5.25 | 16.42 | 16.89 | 0.23 | 0.9 | -13.23 |
Changes in Other Operating Activities | -2.98 | -1.43 | 0.2 | 27.42 | -1.43 | -5.24 |
Operating Cash Flow | 34.54 | -46.91 | -128.51 | -70.3 | -77.31 | -48.73 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Capital Expenditures | - | - | - | -0.72 | -0.03 | -0.1 |
Purchases of Investments | -60.96 | -276 | -237.23 | -3.41 | -61.77 | -131.41 |
Proceeds from Sale of Investments | 86.69 | 327.78 | 187.14 | 83.83 | 102.22 | 36.28 |
Proceeds from Business Divestments | - | - | - | - | 16.5 | 25.5 |
Investing Cash Flow | 10.54 | 51.78 | -50.09 | 79.7 | 56.93 | -69.72 |
Financing Activities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Long-Term Debt Issued | - | - | 30 | - | - | - |
Long-Term Debt Repaid | - | - | -38.67 | -8.65 | - | - |
Net Long-Term Debt Issued (Repaid) | - | - | -8.67 | -8.65 | - | - |
Issuance of Common Stock | 5.06 | 15.97 | 148.36 | 28 | 0.26 | 179.68 |
Net Common Stock Issued (Repurchased) | 5.06 | 15.97 | 148.36 | 28 | 0.26 | 179.68 |
Other Financing Activities | - | - | -4.36 | -4.8 | - | - |
Financing Cash Flow | 5.06 | 15.97 | 135.34 | 14.54 | 0.26 | 179.68 |
Net Cash Flow
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Foreign Exchange Rate Adjustments | 1.09 | -0.64 | 0.46 | -0.66 | -0.9 | 0.72 |
Net Cash Flow | 51.23 | 20.2 | -42.81 | 23.27 | -21.01 | 61.95 |
Beginning Cash & Cash Equivalents | - | 31.17 | 73.98 | 50.71 | 71.72 | 9.77 |
Free Cash Flow
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | 34.54 | -46.91 | -128.51 | -71.02 | -77.34 | -48.83 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | 13.90% | -27.74% | -459.58% | - | - | -218.64% |
Free Cash Flow Per Share | 0.35 | -0.49 | -1.60 | -1.18 | -1.32 | -0.89 |
Levered Free Cash Flow | 2.15 | -44.47 | -158.07 | -120.81 | -72.85 | -13.99 |
Unlevered Free Cash Flow | 6.96 | -37.83 | -126.55 | -96.27 | -66.54 | -29.05 |